The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 Billion by 2021 from USD 1.35 Billion in 2016 at a CAGR of 16.4% during the forecast period. The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period.

North America dominated the global market in 2016, with the U.S. accounting for a major share of this regional market. Factors such as high incidence of chromosomal abnormalities, increasing maternal age, and increasing awareness programs are likely to drive the growth of the North American market.

The Asian market is projected to grow at the highest CAGR during the forecast period owing to the increasing disposable income, rising awareness programs and conferences, and rising focus of market players to expand their presence in this region. Some prominent markets in Asia include China, India, and Japan.

Get More Information: https://www.marketsandmarkets.com/Market-Reports/non-invasive-prenatal-testing-market-145607690.html

The market is fragmented with several global as well as local players. Players offer several products across different subsegments of this market. Key players in this market include GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]